MRVI / Maravai LifeSciences Holdings, Inc. - SEC备案- 年度报告、委托书

and Restricted Stock Unit Agreement (2025 RSU Award Agreement - Chairman of

Exhibit 10.6 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”

MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base business revenue, which exclu

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base business revenue, which excludes revenue from high-volume CleanCap® for commercialized vaccine programs, grew 5% year-over-year Net Loss Reduction, Positive Adjusted

orm of Stock Option Grant Notice and Stock Option Agreement (2025 Executive New Hire Grant)

Exhibit 10.4 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN STOCK OPTION GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”) the sto

Notice and Restricted Stock Unit Agreement (2025 Executive New Hi

Exhibit 10.3 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”

orm of Performance Stock Unit Grant Notice and Performance Stock Unit Agreement (2025

Exhibit 10.5 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN PERFORMANCE STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39725 Mar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Maravai LifeScienc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)

cted Stock Unit Grant Notice and Restricted S

Exhibit 10.7 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”

Letter of Ernst & Young LLP to the Securities and Exchange Commission, dated July

Exhibit 16.1 July 18, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated July 18, 2025, of Maravai LifeSciences Holdings, Inc. and are in agreement with the statements contained in the second sentence in the first paragraph and the second, third, fourth and fifth paragraphs on page 1 therein. We have no basis to a

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (

Employment Agreement, effective as of June 30, 2025, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Rajesh Asarpota.

Exhibit 10.1 Execution Version EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is dated as of June 25, 2025 and effective as of the Effective Date (as defined below), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Rajesh Asarpota (“Executive”). Capitali

Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer

Exhibit 99.1 Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer SAN DIEGO, Calif., June 25, 2025 — Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Rajesh “Raj” Asarpota has been appointed Executive Vice President (EVP) and Chief Financial Officer (CFO), effe

Employment Agreement of Bernd Brust, effective as of June 8, 2025, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Bernd Brust.

EX-10.1 Exhibit 10.1 Execution Version EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is dated as of June 8, 2025 and effective as of the Effective Date (as defined below), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Bernd Brust (“Executive”). Capit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2025 Maravai LifeSciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (C

Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors

EX-99.1 Exhibit 99.1 Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors SAN DIEGO, Calif., June 9, 2025 — Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39725 Ma

Filing Fee Table.

Exhibit 107 FEE TABLES FOR FORM S-8 Calculation of Filing Fee Tables Form S-8 (Form Type) Maravai LifeSciences Holdings, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Maravai LifeSciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (C

As filed with the Securities and Exchange Commission on May 12, 2025

As filed with the Securities and Exchange Commission on May 12, 2025 Registration No.

MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS SAN DIEGO, Calif., — May 12, 2025 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Hig

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)

Separation Agreement and General Release of Claims by and between TriLink Biotechnologies, LLC, and Andrew Burch, dated as of January 17, 2025.

Exhibit 10.42 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS This Confidential Separation Agreement and General Release of Claims (this “Agreement” or “Release”) is entered into between Drew Burch (“you”) and TriLink BioTechnologies, LLC (the “Company”). You and the Company (together, the “Parties”) agree as follows: Termination of Employment Relationship: Your employment relation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 Maravai LifeScienc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)

List of subsidiaries of Maravai LifeSciences Holdings, Inc.

Exhibit 21.1 Subsidiaries of the Registrant Subsidiaries of Maravai LifeSciences Holdings, Inc. Maravai Topco Holdings, LLC (Delaware) Subsidiaries of Maravai Topco Holdings, LLC Maravai Intermediate Holdings, LLC (Delaware) Subsidiaries of Maravai Intermediate Holdings, LLC Alphazyme, LLC (Delaware) Cygnus Technologies, LLC (Delaware) Maravai LifeSciences International Holdings, Inc. (Delaware) M

MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Schedules Conference Call for Thursday, March 20, 2025

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Schedules Conference Call for Thursday, March 20, 2025 SAN DIEGO, Calif., — March 18, 2025 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter

nsider Trading Policy

Amended and Restated effective as of November 15, 2024 AMENDED AND RESTATED INSIDER TRADING POLICY MARAVAI LIFESCIENCES HOLDINGS, INC.

Description of Maravai LifeSciences Holdings, Inc.’s Securities.

Exhibit 4.2 Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934. General As of December 31, 2024, Maravai LifeSciences Holdings, Inc. (the “Company,” “we,” “our,” and “us”) had one class of securities, our Class A common stock, par value $0.01 per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended. T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39725 CUSIP NUMBER 56600D107 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra

MARAVAI LIFESCIENCES POSTPONES ITS FOURTH QUARTER AND FULL YEAR 2024 EARNINGS RELEASE AND CONFERENCE CALL

Exhibit 99.1 MARAVAI LIFESCIENCES POSTPONES ITS FOURTH QUARTER AND FULL YEAR 2024 EARNINGS RELEASE AND CONFERENCE CALL SAN DIEGO, Calif., — February 25, 2025 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that it is postponing its previously announced earnings release and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 Maravai LifeSci

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio

Maravai LifeSciences Holdings, Inc. February 19, 2025

Maravai LifeSciences Holdings, Inc. February 19, 2025 Via EDGAR Submission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Christine Torney, Kevin Vaughn Re: Maravai LifeSciences Holdings, Inc. Form 10-K for the Year Ended December 31, 2023 File No. 001-39725 Ladies and Gentlemen: We are writing to respond to the c

Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue Announces Earnings Release Date

Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue Announces Earnings Release Date SAN DIEGO, CA – January 8, 2025 - Maravai LifeSciences Holdings, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 Maravai LifeScien

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 Maravai LifeSci

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (2024 RSU Award).

2024RSUAE MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”) t

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (202

2025RSUAE MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”) t

Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors Carl Hull to Retire as Executive Chairman

Exhibit 99.1 Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors Carl Hull to Retire as Executive Chairman SAN DIEGO, Calif.; – December 5, 2024 - Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from hi

MRVI / Maravai LifeSciences Holdings, Inc. / Point72 Asset Management, L.P. - MARAVAI LIFESCIENCES HOLDINGS, INC. Passive Investment

SC 13G/A 1 p24-3157sc13ga.htm MARAVAI LIFESCIENCES HOLDINGS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D107 (CUSIP Number) September 30, 2024 (Date of Event Which Req

MRVI / Maravai LifeSciences Holdings, Inc. / MARAVAI LIFE SCIENCES HOLDINGS 2, LLC - SC 13G/A Passive Investment

SC 13G/A 1 d873306dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D 107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing o

MRVI / Maravai LifeSciences Holdings, Inc. / 12 West Capital Management LP - MARAVAI LIFESCIENCES HOLDINGS, INC. Passive Investment

SC 13G/A 1 p24-3081sc13ga.htm MARAVAI LIFESCIENCES HOLDINGS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D107 (CUSIP Number) September 30, 2024 (Date of Event Which Req

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3972

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation

MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&D

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&D SAN DIEGO, Calif., — November 7, 2024 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators,

MRVI / Maravai LifeSciences Holdings, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment

SC 13G/A 1 MRVISC13GA1Oct2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) MARAVAI LIFESCIENCES HOLDINGS, INC. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 56600D107 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this

Third Amendment to Credit Agreement, dated September 10, 2024, among Maravai Intermediate Holdings, LLC, Cygnus Technologies, LLC, TriLink Biotechnologies, LLC, Maravai Topco Holdings, LLC, Morgan Stanley Senior Funding, Inc. and the other lenders and parties thereto.

Execution Version THIRD AMENDMENT TO CREDIT AGREEMENT This THIRD AMENDMENT TO CREDIT AGREEMENT, dated as of September 10, 2024 (this “Amendment”), shall, on, and subject to the occurrence of, the Revolver Extension and Amendment Date (as defined below), amend that certain Credit Agreement, dated as of October 19, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporati

MARAVAI LIFESCIENCES HOLDINGS, INC. August 16, 2024

MARAVAI LIFESCIENCES HOLDINGS, INC. August 16, 2024 Via EDGAR Submission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Christine Torney Kevin Vaughn Re: MARAVAI LIFESCIENCES HOLDINGS, INC. Form 10-K for the Year Ended December 31, 2023 File No. 001-39725 Ladies and Gentlemen: We write in response to commen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39725 Mar

MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation SAN DIEGO, Calif., — August 7, 2024 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)

Maravai LifeSciences Appoints Trey Martin to Board of Directors Maravai announces the appointment of CEO Trey Martin to its Board of Directors, highlighting his leadership, commitment to innovation, and industry experience

Exhibit 99.1 Maravai LifeSciences Appoints Trey Martin to Board of Directors Maravai announces the appointment of CEO Trey Martin to its Board of Directors, highlighting his leadership, commitment to innovation, and industry experience SAN DIEGO, July 29, 2024 - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 Maravai LifeScience

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (

MARAVAI LIFESCIENCES HOLDINGS, INC. June 25, 2024

MARAVAI LIFESCIENCES HOLDINGS, INC. June 25, 2024 Via EDGAR Submission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-3628 Attention: Christine Torney Kevin Vaughn Re: MARAVAI LIFESCIENCES HOLDINGS, INC. Form 10-K For the Year Ended December 31, 2023 File No. 001-39725 Ladies and Gentlemen: On behalf of Maravai LifeSciences

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned ackn

MRVI / Maravai LifeSciences Holdings, Inc. / Point72 Asset Management, L.P. - MARAVAI LIFESCIENCES HOLDINGS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D107 (CUSIP Number) June 7, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (C

MRVI / Maravai LifeSciences Holdings, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MARAVAI LIFESCIENCES HOLDINGS, INC. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 56600D107 (CUSIP Number) MAY 9, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39725 Ma

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (January 2024) (incorporated by reference to Exhibit 10.1 to Maravai LifeSciences Holdings, Inc.’s Form 10-Q filed on May 9, 2024).

Exhibit 10.1 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”

ment Agreement of Andrew Burch, effective as of February 25, 2024, among Maravai LifeSciences Holdings, Inc., TriLink Biotechnologies, LLC and And

Exhibit 10.2 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of February 25, 2024 (the “Effective Date”), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), TriLink Biotechnologies, LLC, a Delaware limited liability company (“Employer”), and Andrew Burch (“Executive”). Capita

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (Co

MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation SAN DIEGO, Calif., — May 8, 2024 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

between 10240 Flanders Investors LL

Exhibit 10.15 LEASE AGREEMENT BETWEEN 10240 FLANDERS INVESTORS LLC, a Delaware limited liability company (LANDLORD) AND TRILINK BIOTECHNOLOGIES, LLC, a Delaware limited liability company (TENANT) August 6, 2021 10240-10247 FLANDERS COURT SAN DIEGO, CALIFORNIA TABLE OF CONTENTS Page The table of contents is empty. Heading styles must be applied in the document and be selected in the table of conten

Amendment No.1, effective as of July 27, 2023, to the Amended and Restated Employment Agreement of Carl W. Hull, dated May 8, 2023, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Carl W. Hull (incorporated by reference to Exhibit 10.24 to Maravai LifeSciences Holdings, Inc.’s Form 10-K filed on February 29, 2024).

Exhibit 10.24 AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”), entered into on July 27, 2023 (the “Effective Date”), is by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Carl W

Second Amendment to Lease Agreement, dated October 1, 2022, by and between 10240 Flanders Investors LLC and Tri

Exhibit 10.17 SECOND AMENDMENT TO LEASE AGREEMENT This SECOND AMENDMENT TO LEASE AGREEMENT (“Amendment”) is entered into as of October 1, 2022 (“Effective Date”), by and between 10240 FLANDERS INVESTORS LLC, a Delaware limited liability company (“Landlord”), and TRILINK BIOTECHNOLOGIES, LLC, a Delaware limited liability company (“Tenant”), with reference to the facts set forth in the Recitals belo

Form of Performance Stock Unit Grant Notice and Performance Stock Unit Agreement

Exhibit 10.35 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN PERFORMANCE STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participan

ment to Credit Agreement to Credit Agreement, dated as of Augu

Exhibit 10.21 EXECUTION VERSION FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is dated as of August 11, 2021 and is entered into by and among MARAVAI INTERMEDIATE HOLDINGS, LLC, a Delaware limited liability company (“Parent Borrower”), and MORGAN STANLEY SENIOR FUNDING, INC. (“MS”), as administrative agent for the Lenders (in such capacity, the “Ad

First Amendment to Lease Agreement, dated October 14, 2021, by and between 10240 Flanders Investors LLC and Tri

Exhibit 10.16 FIRST AMENDMENT TO LEASE AGREEMENT This FIRST AMENDMENT TO LEASE AGREEMENT (“Amendment”) is entered into as of October 14, 2021 (“Effective Date”), by and between 10240 FLANDERS fNVESTORS LLC, a Delaware limited liability company (“Landlord”), and TRILINK BIOTECHNOLOGIES, LLC, a Delaware limited liability company (“Tenant”), with reference to the facts set forth in the Recitals below

Clawback Policy of Maravai LifeSciences Holdings, Inc. (incorporated by reference to Exhibit 97.1 to Maravai LifeSciences Holdings, Inc.’s Form 10-K filed on February 29, 2024).

Exhibit 97.1 Effective October 2, 2023 CLAWBACK POLICY MARAVAI LIFESCIENCES HOLDINGS, INC. PURPOSE Maravai LifeSciences Holdings, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Company’s

List of subsidiaries of Maravai LifeSciences Holdings, Inc.

Exhibit 21.1 Subsidiaries of the Registrant Subsidiaries of Maravai LifeSciences Holdings, Inc. Maravai Topco Holdings, LLC (Delaware) Subsidiaries of Maravai Topco Holdings, LLC Maravai Intermediate Holdings, LLC (Delaware) Subsidiaries of Maravai Intermediate Holdings, LLC Alphazyme, LLC (Delaware) Cygnus Technologies, LLC (Delaware) Maravai LifeSciences International Holdings, Inc. (Delaware) M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact

(incorporated by reference to Exhibit 10.33 to Maravai LifeSciences Holdings, Inc.

Exhibit 10.33 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN STOCK OPTION GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”) the st

ed Stock Unit Grant Notice and Restricted Stock Unit Agreement.

Exhibit 10.34 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant

d as of June 11, 2021, by and between

Exhibit 10.18 LEASE AGREEMENT BETWEEN CIGG, LLC Landlord AND CYGNUS TECHNOLOGIES, LLC Tenant DATED: June 11, 2021 1 LEASE THIS LEASE (this “Lease”) is entered into this June 11, 2021 (the date of execution of this Lease by authorized parties of Landlord and Tenant shall be the “Effective Date”), by and between CIGG, LLC, a North Carolina limited liability company, having its principal place of bus

Description of Maravai LifeSciences Holdings, Inc.’s Securities.

Exhibit 4.2 Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934. General As of December 31, 2023, Maravai LifeSciences Holdings, Inc. (the “Company,” “we,” “our,” and “us”) had one class of securities, our Class A common stock, par value $0.01 per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended. T

MRVI / Maravai LifeSciences Holdings, Inc. / 12 West Capital Management LP - MARAVAI LIFESCIENCES HOLDINGS, INC. Passive Investment

SC 13G/A 1 p24-1054sc13ga.htm MARAVAI LIFESCIENCES HOLDINGS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D107 (CUSIP Number) December 31, 2023** (Date of Event Which Re

JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k)

EX-99 2 exhibit99.htm JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio

MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation

EX-99.1 2 exhibit991-q42023.htm EX-99.1 Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation SAN DIEGO, Calif., — February 22, 2024 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech

MRVI / Maravai LifeSciences Holdings, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01397-maravailifesciencesh.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Maravai Lifesciences Holdings, Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 56600D107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check th

MRVI / Maravai LifeSciences Holdings, Inc. / MARAVAI LIFE SCIENCES HOLDINGS 2, LLC - SC 13G/A Passive Investment

SC 13G/A 1 d63977dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D 107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of

MRVI / Maravai LifeSciences Holdings, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) MARAVAI LIFESCIENCES HOLDINGS, INC. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 56600D107 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate bo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, In

MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS Announces Realignment to Drive Operational Efficiencies and Streamline the Business Post-Pandemic Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innov

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS Announces Realignment to Drive Operational Efficiencies and Streamline the Business Post-Pandemic Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation SAN DIEGO, Calif., — November 7, 2023 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life sci

MRVI / Maravai LifeSciences Holdings Inc - Class A / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* MARAVAI LIFESCIENCES HOLDINGS INC (Name of Issuer) Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) October 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appro

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation

MRVI / Maravai LifeSciences Holdings Inc - Class A / MILLENNIUM MANAGEMENT LLC Passive Investment

SC 13G 1 MRVISC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MARAVAI LIFESCIENCES HOLDINGS, INC. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 56600D107 (CUSIP Number) OCTOBER 20, 2023 (Date of event which requires filing of this statement) Check the appropriat

Form of Amendment No. 1 to Stock Option Grant Notice.

EXHIBIT 10.2 AMENDMENT NO. 1 TO STOCK OPTION GRANT NOTICE This AMENDMENT NO. 1 TO STOCK OPTION GRANT NOTICE (this “Amendment”) is entered into effective as of [], 2023 (the “Amendment Effective Date”), by and between Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”) and [] (“Participant”). Capitalized terms used but not defined herein shall have the meanings ascribed to s

Form of Amendment No. 1 to Restricted Stock Unit Grant Notice.

EXHIBIT 10.1 AMENDMENT NO. 1 TO RESTRICTED STOCK UNIT GRANT NOTICE This AMENDMENT NO. 1 TO RESTRICTED STOCK UNIT GRANT NOTICE (this “Amendment”) is entered into effective as of [], 2023 (the “Amendment Effective Date”), by and between Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”) and [] (“Participant”). Capitalized terms used but not defined herein shall have the mean

Amendment No. 1 to Performance Stock Unit Grant Notice by and between

EXHIBIT 10.3 AMENDMENT NO. 1 TO PERFORMANCE STOCK UNIT GRANT NOTICE This AMENDMENT NO. 1 TO PERFORMANCE STOCK UNIT GRANT NOTICE (this “Amendment”) is entered into effective as of July 6, 2023 (the “Amendment Effective Date”), by and between Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”) and William E. Martin, III (“Participant”). Capitalized terms used but not defined

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 Maravai LifeScienc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)

MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation SAN DIEGO, Calif., — August 7, 2023 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results

Maravai LifeSciences Announces Completion of Planned CEO Leadership Transition William “Trey” Martin, III assumes the role of Maravai’s CEO Carl Hull to continue to serve as Executive Chairman

Exhibit 99.1 Maravai LifeSciences Announces Completion of Planned CEO Leadership Transition William “Trey” Martin, III assumes the role of Maravai’s CEO Carl Hull to continue to serve as Executive Chairman SAN DIEGO, Calif.; – July 27, 2023 - Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and b

Amendment No. 1, effective as of July 27, 2023, to the Amended and Restated Employment Agreement of Carl W. Hull, dated as of May 8, 2023, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate holdings, LLC and Carl W. Hull.

EXHIBIT 10.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”), entered into on July 27, 2023 (the “Effective Date”), is by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Carl W.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (

Maravai LifeSciences Announces Appointment of New Director to the Board

Exhibit 99.1 Maravai LifeSciences Announces Appointment of New Director to the Board SAN DIEGO – July 20, 2023 - Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Robert (“Chip”) Hance has stepped down from the Company’s Board of Directors (the “Board”) effec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 Maravai LifeScience

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 Maravai LifeSciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (C

8, 2023, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and William

Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of May 8, 2023 (the “Effective Date”), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and William “Trey” Martin, III (“Executive”). Capita

Employment Agreement by and among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC, and Peter M. Leddy

Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is signed as of June 21, 2022, and effective as of June 27, 2022 (the “Effective Date”), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Peter M. Leddy (“Executive”). Capitalized terms used but

Amended and Restated Employment Agreement of Christine Dolan, dated as of May 8, 2023 among Maravai LifeSciences Holdings, Inc., Cygnus Technologies, LLC, MLSC Holdings, LLC and Christine Dolan (incorporated by reference to Exhibit 10.6 to Maravai LifeSciences Holdings, Inc.’s Form 10-Q filed on May 9, 2023).

Exhibit 10.6 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of May 8, 2023 (the “Effective Date”), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Cygnus Technologies, LLC, a Delaware limited liability company (“Employer”), MLSC Holdings, LLC, a Delaware limited liability company (“MLS

Amended and Restated Employment Agreement by and among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Peter M. Leddy, Ph.D., dated as of May 8, 2023.

Exhibit 10.5 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of May 8, 2023 (the “Effective Date”), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Peter M. Leddy, Ph.D. (“Executive”). Capitalized

Amended and Restated Employment Agreement of Kevin Herde, dated May 8, 2023, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Kevin Herde (incorporated by reference to Exhibit 10.4 to Maravai LifeSciences Holdings, Inc.’s Form 10-Q filed on May 9, 2023).

Exhibit 10.4 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made as of May 8, 2023, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Kevin Herde (“Executive”). Capitalized terms used but not otherwise defined

Amended and Restated Employment Agreement by and among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Carl W. Hull, dated as of May 8, 2023.

Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of May 8, 2023, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Carl W. Hull (“Executive”). Capitalized terms used but not otherwise de

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 Maravai LifeSciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (Co

MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation SAN DIEGO, Calif., — May 8, 2023 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( as permitted by Rule 14a-6(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 Maravai LifeScience

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Maravai LifeScienc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)

Description of Maravai LifeSciences Holdings, Inc.’s Securities.

Exhibit 4.2 Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934. General As of December 31, 2022, Maravai LifeSciences Holdings, Inc. (the “Company,” “we,” “our,” and “us”) had one class of securities, our Class A common stock, par value $0.01 per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended. T

List of subsidiaries of Maravai LifeSciences Holdings, Inc.

Exhibit 21.1 Subsidiaries of the Registrant Subsidiaries of Maravai LifeSciences Holdings, Inc. Maravai Topco Holdings, LLC (Delaware) Subsidiaries of Maravai Topco Holdings, LLC Maravai Intermediate Holdings, LLC (Delaware) Alphazyme, LLC (Delaware) Subsidiaries of Maravai Intermediate Holdings, LLC TriLink Biotechnologies, LLC (Delaware) Glen Research, LLC (Delaware) MockV Solutions, Inc. (Maryl

Form of Senior Management Agreement - Capital Units and Incentive Units (incorporated by reference to Exhibit 10.4 to Maravai LifeSciences Holdings, Inc.’s Form 10-K filed on February 28, 2023).

EXHIBIT 10.4 FORM OF SENIOR MANAGEMENT AGREEMENT (CAPITAL UNITS AND INCENTIVE UNITS) THIS SENIOR MANAGEMENT AGREEMENT (this “Agreement”) is made as of [●], by and among Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (the “Company”), [Maravai Life Sciences, Inc.], a Delaware corporation (“Employer”), and [●] (“Executive”). Capitalized terms used but not otherwise defined

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact

Form of Amendment to Senior Management Agreement (incorporated by reference to Exhibit 10.6 to Maravai LifeSciences Holdings, Inc.’s Form 10-K filed on February 28, 2023).

EXHIBIT 10.6 FORM OF AMENDMENT TO SENIOR MANAGEMENT AGREEMENT THIS AMENDMENT TO THE SENIOR MANAGEMENT AGREEMENT (this “Amendment”), effective as of [●], is made by and among Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (the “Company”), [●]1 (“Employer”), [●] (“Executive”), GTCR Fund XI/B LP, a Delaware limited partnership (“Fund XI/B”), GTCR/Maravai Splitter LP, a Dela

Form of Senior Management Agreement - Incentive Units (incorporated by reference to Exhibit 10.5 to Maravai LifeSciences Holdings, Inc.’s Form 10-K filed on February 28, 2023).

EXHIBIT 10.5 FORM OF SENIOR MANAGEMENT AGREEMENT (INCENTIVE UNITS) THIS SENIOR MANAGEMENT AGREEMENT (this “Agreement”) is made as of [●], by and among Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (the “Company”), [●]1 (“Employer”), and [●] (“Executive”). Capitalized terms used but not otherwise defined herein shall have the meanings set forth in Section 8 of this Agree

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Maravai LifeSci

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio

MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS Base business revenues, excluding COVID-19 related CleanCap® revenues, were up 67% in the fourth quarter and up 17% for the full year Announces acquisition of privately-

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS Base business revenues, excluding COVID-19 related CleanCap® revenues, were up 67% in the fourth quarter and up 17% for the full year Announces acquisition of privately-held Alphazyme, LLC, adding critical enzyme manufacturing capabilities to Maravai’s Nucleic Acid Production Segment SAN DIEGO, Calif., —

MRVI / Maravai LifeSciences Holdings, Inc. Class A / Select Equity Group, L.P. - SCHEDULE 13G/A, AMENDMENT #3 Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whic

EXHIBIT 99.1

EXHIBIT 99.1 The identity and the Item 3 classification of the relevant subsidiary are: Select Equity Group, L.P., which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

MRVI / Maravai LifeSciences Holdings, Inc. Class A / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01363-maravailifesciencesh.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Maravai LifeSciences Holdings Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 56600D107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the

MRVI / Maravai LifeSciences Holdings, Inc. Class A / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* MARAVAI LIFESCIENCES HOLDINGS INC (Name of Issuer) Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Maravai LifeScie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Maravai LifeSciences Holdings, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39725 85-2786970 (State or Other Jurisdiction of Incorporation) (C

Maravai LifeSciences Announces Updated CEO Leadership Transition Plans Maravai announces plans for William “Trey” Martin, III to serve as President of its Biologics Safety Testing Segment and its expectation that he will then assume the role of Marav

Exhibit 99.1 Maravai LifeSciences Announces Updated CEO Leadership Transition Plans Maravai announces plans for William ?Trey? Martin, III to serve as President of its Biologics Safety Testing Segment and its expectation that he will then assume the role of Maravai?s CEO in July 2023 Carl Hull to continue to serve as Executive Chairman and Interim CEO SAN DIEGO, Calif.; ? December 1, 2022?Maravai

EXHIBIT 99.1

EXHIBIT 99.1 The identity and the Item 3 classification of the relevant subsidiary are: Select Equity Group, L.P., which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

MRVI / Maravai LifeSciences Holdings, Inc. Class A / Select Equity Group, L.P. - SCHEDULE 13G/A, AMENDMENT #2 Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) October 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which

Amendment No. 2, dated as of August 30, 2022, to the Agreement and Plan of Merger, dated as of August 5, 2021, among Maravai Life Sciences, LLC (f/k/a Maravai Life Sciences, Inc.), Voyager Group Holdings, Inc., Vector Laboratories, Inc., Maravai LifeSciences Holdings, Inc., and Maravai Intermediate Holdings, LLC (incorporated by reference to Exhibit 2.1 to Maravai LifeSciences Holdings, Inc.’s Form 10-Q filed on November 4, 2022).

Exhibit 2.1 AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER (this ?Amendment?), is made as of August 30, 2022, by and among Maravai Life Sciences, LLC, a Delaware limited liability company (f/k/a Maravai Life Sciences, Inc.) (?Seller?), Voyager Group Holdings, Inc., a Delaware corporation (?Parent?), Vector Laboratories, Inc., a California corpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, In

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation

MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Updates Revenue, Adjusted EBITDA and Adjusted EPS Guidance for 2022

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Updates Revenue, Adjusted EBITDA and Adjusted EPS Guidance for 2022 SAN DIEGO, Calif., ? November 2, 2022 ? Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter e

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation

Maravai LifeSciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation Maravai LifeSciences and Recently-Appointed CEO Trey Martin Vigorously Defending Against Suit

Exhibit 99.1 Maravai LifeSciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation Maravai LifeSciences and Recently-Appointed CEO Trey Martin Vigorously Defending Against Suit SAN DIEGO, Calif., ? October 19, 2022 ? Executive Chairman and former CEO of Maravai LifeSciences, Inc. (NASDAQ: MRVI) Carl Hull, has been reinstated as CEO of the company on an interim basis

Form of Performance Stock Unit Grant Notice and Performance Stock Unit Agreement (incorporated by reference to Exhibit 10.5 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on October 3, 2022).

EXHBIT 10.5 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN PERFORMANCE STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the ?Plan?), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the ?Company?), hereby grants to the individual listed below (?Participant?

Maravai LifeSciences Announces CEO Leadership Transition -William “Trey” Martin, III appointed to succeed Carl Hull as Chief Executive Officer - Hull to Serve as Executive Chairman of the Board of Directors

Maravai LifeSciences Announces CEO Leadership Transition -William ?Trey? Martin, III appointed to succeed Carl Hull as Chief Executive Officer - Hull to Serve as Executive Chairman of the Board of Directors SAN DIEGO, Calif.

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.2 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on October 3, 2022).

EXHIBIT 10.2 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the ?Plan?), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the ?Company?), hereby grants to the individual listed below (?Participant?

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.3 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on October 3, 2022).

EXHIBIT 10.3 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the ?Plan?), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the ?Company?), hereby grants to the individual listed below (?Participant?

Amendment No.1, effective as of September 30, 2022, to the Employment Agreement of Carl W. Hull, dated November 24, 2020, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Carl W. Hull (incorporated by reference to Exhibit 10.6 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on October 3, 2022).

EXHIBIT 10.6 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?), entered into on September 29, 2022 is by and between Maravai LifeSciences Holdings, Inc., a Delaware corporation (?Parent?), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (?Employer?), and Carl W. Hull (?Executive?). WHEREAS, Executive, Parent and Employer are party

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporati

Employment Agreement of William “Trey” Martin, III, effective as of September 30, 2022, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and William “Trey” Martin, III (incorporated by reference to Exhibit 10.1 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on October 3, 2022).

EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is signed as of September 29, 2022, and effective as of September 30, 2022 (the ?Effective Date?), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (?Parent?), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (?Employer?), and William ?Trey? Martin, III (?Executive?). Capi

MRVI / Maravai LifeSciences Holdings, Inc. Class A / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* MARAVAI LIFESCIENCES HOLDINGS INC (Name of Issuer) Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) August 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

MRVI / Maravai LifeSciences Holdings, Inc. Class A / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* MARAVAI LIFESCIENCES HOLDINGS INC (Name of Issuer) Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) August 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (E

MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Record First Half Revenue, Net Income, Adjusted EBITDA and EPS

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Record First Half Revenue, Net Income, Adjusted EBITDA and EPS SAN DIEGO, Calif., ? August 4, 2022 ? Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)

MARAVAI LIFESCIENCES HOLDINGS, INC. July 12, 2022

CORRESP 1 filename1.htm MARAVAI LIFESCIENCES HOLDINGS, INC. July 12, 2022 Via EDGAR Submission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-3628 Attention: Vanessa Robertson Christine Torney Re: MARAVAI LIFESCIENCES HOLDINGS, INC. Form 10-K For the Year Ended December 31, 2021 File No. 001-39725 Ladies and Gentlemen: On be

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (

Employment Agreement, dated as of November 24, 2020 among Maravai LifeSciences Holdings, Inc., Vector Laboratories, Inc. and Lisa Sellers.

Exhibit 10.3 EXECUTION VERSION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (?Parent?), Vector Laboratories, Inc., a California corporation (?Employer?), and Lisa Sellers (?Executive?). Capitalized terms used but not otherwise defined herein shall have the meanings set for

Employment Agreement, dated as of November 24, 2020 among Maravai LifeSciences Holdings, Inc., Cygnus Technologies, LLC, MLSC Holdings, LLC and Christine Dolan.

Exhibit 10.1 EXECUTION VERSION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this "Agreement") is made as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation ("Parent"), Cygnus Technologies, LLC, a Delaware limited liability company ("Employer"), MLSC Holdings, LLC, a Delaware limited liability company (?MLSC?), and Christine Dolan ("Executive"). Capita

Employment Agreement, dated as of November 24, 2020 among Maravai LifeSciences Holdings, LLC, Maravai Intermediate Holdings, LLC and Kurt Oreshack.

Exhibit 10.2 EXECUTION VERSION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (?Parent?), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (?Employer?), and Kurt Oreshack (?Executive?). Capitalized terms used but not otherwise defined herein shall hav

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (Co

MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS Affirms Revenue Guidance and Raises Adjusted EBITDA and Adjusted EPS Guidance

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS Affirms Revenue Guidance and Raises Adjusted EBITDA and Adjusted EPS Guidance SAN DIEGO, Calif., — May 5, 2022 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A 1 d343471ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissi

List of subsidiaries of Maravai LifeSciences Holdings, Inc.

Exhibit 21.1 Subsidiaries of the Registrant Subsidiaries of Maravai LifeSciences Holdings, Inc. Maravai Topco Holdings, LLC (Delaware) Subsidiaries of Maravai Topco Holdings, LLC Maravai Intermediate Holdings, LLC (Delaware) Subsidiaries of Maravai Intermediate Holdings, LLC TriLink Biotechnologies, LLC (Delaware) Glen Research, LLC (Delaware) MockV Solutions, Inc. (Maryland) Cygnus Technologies,

Description of Maravai LifeSciences Holdings, Inc.’s Securities.

Exhibit 4.2 Description of Registrant?s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934. General As of December 31, 2021, Maravai LifeSciences Holdings, Inc. (the ?Company,? ?we,? ?our,? and ?us?) had one class of securities, our Class A common stock, par value $0.01 per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended. T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact

Letter Agreement, dated November 24, 2021, amending the Agreement and Plan of Merger, dated as of August 5, 2021, among Maravai Life Sciences, Inc., Voyager Group Holdings, Inc., Maravai LifeSciences Holdings, Inc., and Maravai Intermediate Holdings, LLC (incorporated by reference to Exhibit 2.3 to Maravai LifeSciences Holdings, Inc.'s Form 10-K filed on March 1, 2022).

EXHIBIT 2.3 Voyager Group Holdings, Inc. c/o Thompson Street Capital Partners VI, L.P. 7676 Forsyth Blvd., Suite 2700 Saint Louis, Missouri 63105 November 24, 2021 VIA EMAIL AND COURIER SERVICES Maravai Life Sciences, Inc. 10770 Wateridge Circle Suite 200 San Diego, California 92121 Email: [email protected] Re: Extension of Period to Deliver the Closing Statement Mr. Oreshack: Reference is

MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND UPDATES 2022 FINANCIAL GUIDANCE

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND UPDATES 2022 FINANCIAL GUIDANCE SAN DIEGO, Calif., ? February 23, 2022 ? Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and the full yea

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio

MRVI / Maravai LifeSciences Holdings, Inc. Class A / D1 Capital Partners L.P. - MARAVAI LIFESCIENCES HOLDINGS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, $0.01 par value (Title of Class of Securities) 56600D107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r

MRVI / Maravai LifeSciences Holdings, Inc. Class A / Select Equity Group, L.P. - SCHEDULE 13G (AMENDMENT NO. 3) Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whic

EXHIBIT 99.1

EXHIBIT 99.1 The identity and the Item 3 classification of the relevant subsidiary are: Select Equity Group, L.P., which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

MRVI / Maravai LifeSciences Holdings, Inc. Class A / MARAVAI LIFE SCIENCES HOLDINGS 2, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D 107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the Appropriate

MRVI / Maravai LifeSciences Holdings, Inc. Class A / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Maravai LifeSciences Holdings Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 56600D107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which th

MRVI / Maravai LifeSciences Holdings, Inc. Class A / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MARAVAI LIFESCIENCES HOLDINGS INC (Name of Issuer) Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation

Maravai LifeSciences Acquires MyChem, a Leader in Proprietary Ultra-Pure Nucleotides MyChem’s nucleotide synthesis methods are highly complementary to Maravai’s Trilink mRNA technologies Increases capabilities serving the high growth cell and gene th

Maravai LifeSciences Acquires MyChem, a Leader in Proprietary Ultra-Pure Nucleotides MyChem?s nucleotide synthesis methods are highly complementary to Maravai?s Trilink mRNA technologies Increases capabilities serving the high growth cell and gene therapy market SAN DIEGO, Calif.

Amendment No. 2, dated as of January 19, 2022, to the Credit Agreement, dated as of October 19, 2020, among Maravai Intermediate Holdings, LLC, Cygnus Technologies, LLC, Trilink Biotechnologies, LLC, Maravai Topco Holdings, LLC and Morgan Stanley Senior Funding, Inc. (incorporated by reference to Exhibit 10.1 to Maravai LifeSciences Holdings Inc.’s Form 8-K filed on January 20, 2022).

SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT, dated as of January 19, 2022 (this ?Amendment?), amends that certain Credit Agreement, dated as of October 19, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified prior to the Second Amendment Effective Date (as defined below), the ?Credit Agreement?), among Maravai Intermediate Holding

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, In

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio

MARAVAI LIFESCIENCES REPORTS THIRD QUARTER FINANCIAL RESULTS, UPDATES 2021 FINANCIAL GUIDANCE AND PROVIDES PRELIMINARY REVENUE GUIDANCE FOR 2022

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS THIRD QUARTER FINANCIAL RESULTS, UPDATES 2021 FINANCIAL GUIDANCE AND PROVIDES PRELIMINARY REVENUE GUIDANCE FOR 2022 SAN DIEGO, Calif., ? November 10, 2021 ? Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the thi

MRVI / Maravai LifeSciences Holdings, Inc. Class A / Select Equity Group, L.P. - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) October 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which

EXHIBIT 99.1

EXHIBIT 99.1 The identity and the Item 3 classification of the relevant subsidiary are: Select Equity Group, L.P., which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

EXHIBIT 99.2

EXHIBIT 99.2 AGREEMENT OF REPORTING PERSONS The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each

20,000,000 Shares Class A Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-259366 20,000,000 Shares Class A Common Stock The selling stockholders named in this prospectus are offering 20,000,000 shares of our Class A common stock. We are not selling any shares under this prospectus and we will not receive any proceeds from the sale of shares by the selling stockholders. Our Class A common stock is li

MARAVAI LIFESCIENCES HOLDINGS, INC. September 7, 2021

CORRESP 1 filename1.htm MARAVAI LIFESCIENCES HOLDINGS, INC. September 7, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-1090 Attention: Michael Davis Joe McCann Re: Maravai LifeSciences Holdings, Inc. Registration Statement on Form S-1 (File No. 333-259366) Originally Filed September

[Signature Page Follows]

Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Jefferies LLC 520 Madison Avenue New York, New York 10022 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 September 7, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-1090 Attention: Michael Davis Joe McCann Re: Ma

Form of Underwriting Agreement.

Exhibit 1.1 20,000,000 Shares MARAVAI LIFESCIENCES HOLDINGS, INC. CLASS A COMMON STOCK (PAR VALUE $0.01 PER SHARE) UNDERWRITING AGREEMENT September [?], 2021 1 September [?], 2021 Morgan Stanley & Co. LLC Jefferies LLC Goldman Sachs & Co. LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o Goldman Sachs & Co. LLC 200 W

As filed with the Securities and Exchange Commission on September 7, 2021

Table of Contents As filed with the Securities and Exchange Commission on September 7, 2021 Registration No.

Amendment No. 1, dated as of September 2, 2021, to the Agreement and Plan of Merger, dated as of August 5, 2021, among Maravai Life Sciences, Inc., Voyager Group Holdings, Inc., Maravai LifeSciences Holdings, Inc., and Maravai Intermediate Holdings, LLC

AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (this ?Amendment?), is made as of September 2, 2021, by and among Maravai Life Sciences, Inc., a Delaware corporation (?Seller?), Voyager Group Holdings, Inc., a Delaware corporation (?Parent?), VYGR Merger Sub, Inc., a Delaware corporation (?Merger Sub?), Maravai LifeSciences Holdings, Inc., a Del

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio

Amendment No. 1, effective as of June 6, 2021, to the Supply Agreement, dated as of October 9, 2020, among TriLink Biotechnologies, LLC, Pfizer Inc. and BioNTech SE.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

Confidential Treatment Requested by Maravai Life Sciences Holdings, Inc. Pursuant to 17 C.F.R. Section 200.83 As submitted confidentially to the Securities and Exchange Commission on August 26, 2021 pursuant to the Jumpstart Our Business Startups Act

DRS 1 filename1.htm Table of Contents Confidential Treatment Requested by Maravai Life Sciences Holdings, Inc. Pursuant to 17 C.F.R. Section 200.83 As submitted confidentially to the Securities and Exchange Commission on August 26, 2021 pursuant to the Jumpstart Our Business Startups Act of 2012. This draft registration statement has not been publicly filed with the Securities and Exchange Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (E

Agreement and Plan of Merger, dated as of August 5, 2021, among Maravai Life Sciences, Inc., Voyager Group Holdings, Inc., Maravai LifeSciences Holdings, Inc., and Maravai Intermediate Holdings, LLC (incorporated by reference to Exhibit 2.1 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on August 10, 2021).

EX-2.1 2 exhibit21to8-10x218xkproje.htm EX-2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among MARAVAI LIFE SCIENCES, INC., as Seller, VOYAGER GROUP HOLDINGS, INC., as Parent, VYGR MERGER SUB, INC., as Merger Sub, and MARAVAI LIFESCIENCES HOLDINGS, INC. and MARAVAI INTERMEDIATE HOLDINGS, LLC, as the Maravai Guarantors, Dated as of August 5, 2021 KE 78589182 TABLE OF CONTENTS ARTICLE I

MARAVAI LIFESCIENCES REPORTS SECOND QUARTER FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE SAN DIEGO ? August 10, 2021 ? Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2021, together with other busin

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (

MARAVAI LIFESCIENCES REPORTS FIRST QUARTER FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE

EX-99.1 2 exhibit991-q12021.htm EX-99.1 Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FIRST QUARTER FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE SAN DIEGO — May 10, 2021 — Maravai LifeSciences Holdings, Inc. (Maravai)(NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39725 (Commission F

Schedule 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

- PRE 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

18,000,000 Shares Class A Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-255043 18,000,000 Shares Class A Common Stock The selling stockholders named in this prospectus are offering 18,000,000 shares of our Class A common stock. We are not selling any shares under this prospectus and we will not receive any proceeds from the sale of shares by the selling stockholders. Our Class A common stock is li

- S-1MEF

As filed with the Securities and Exchange Commission on April 7, 2021 Registration No.

Form of Underwriting Agreement.

Exhibit 1.1 [●] Shares MARAVAI LIFESCIENCES HOLDINGS, INC. CLASS A COMMON STOCK (PAR VALUE $0.01 PER SHARE) UNDERWRITING AGREEMENT April [●], 2021 April [●], 2021 Morgan Stanley & Co. LLC Jefferies LLC Goldman Sachs & Co. LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o Goldman Sachs & Co. LLC 200 West Street New Yo

- S-1/A

As filed with the Securities and Exchange Commission on April 6, 2021 Registration No.

-

Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Jefferies LLC 520 Madison Avenue New York, New York 10022 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 April 5, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Re: Maravai LifeSciences Holdings, Inc. Registration

-

CORRESP 1 filename1.htm MARAVAI LIFESCIENCES HOLDINGS, INC. April 5, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-1090 Attention: Abby Adams Re: Maravai LifeSciences Holdings, Inc. Registration Statement on Form S-1 (File No. 333-255043) Originally Filed April 5, 2021 CIK: 0001823239 Ladies and Gentlemen: Maravai LifeSciences Holdings, I

Registration Statement - S-1

Table of Contents As filed with the Securities and Exchange Commission on April 5, 2021 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39725 (Commission

MARAVAI LIFESCIENCES ANNOUNCES PRELIMINARY UNAUDITED FIRST QUARTER REVENUES AND INCOME FROM OPERATIONS RANGE

Exhibit 99.1 MARAVAI LIFESCIENCES ANNOUNCES PRELIMINARY UNAUDITED FIRST QUARTER REVENUES AND INCOME FROM OPERATIONS RANGE SAN DIEGO—Maravai LifeSciences Holdings, Inc. (Maravai or the Company)(NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today provided preliminary unaudited revenue and Income from Operations estimates for the quarter

Confidential Treatment Requested by Maravai LifeSciences Holdings, Inc. Pursuant to 17 C.F.R. Section 200.83 As submitted confidentially to the Securities and Exchange Commission on March 24, 2021 pursuant to the Jumpstart Our Business Startups Act o

DRS 1 filename1.htm Table of Contents Confidential Treatment Requested by Maravai LifeSciences Holdings, Inc. Pursuant to 17 C.F.R. Section 200.83 As submitted confidentially to the Securities and Exchange Commission on March 24, 2021 pursuant to the Jumpstart Our Business Startups Act of 2012. This draft registration statement has not been publicly filed with the Securities and Exchange Commissio

List of subsidiaries of Maravai LifeSciences Holdings, Inc. (incorporated by reference to Exhibit 21.1 to Maravai LifeSciences Holdings, Inc.’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 22, 2021).

Exhibit 21.1 Subsidiaries of the Registrant Subsidiaries of Maravai LifeSciences Holdings, Inc. Maravai Topco Holdings, LLC (Delaware) Subsidiaries of Maravai Topco Holdings, LLC Maravai Intermediate Holdings, LLC (Delaware) Subsidiaries of Maravai Intermediate Holdings, LLC TriLink Biotechnologies, LLC (Delaware) Glen Research, LLC (Delaware) Vector Laboratories, Inc. (California) MockV Solutions

Description of Maravai LifeSciences Holdings, Inc.’s Securities.

EX-4.2 2 mrvi-20orm10xkxex42xdescri.htm EX-4.2 Exhibit 4.2 Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934. General As of December 31, 2020, Maravai LifeSciences Holdings, Inc. (the “Company,” “we,” “our,” and “us”) had one class of securities, our Class A common stock, par value $0.01 per share, registered under Section 12 of the

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact

MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND INITIATES 2021 FINANCIAL GUIDANCE

EX-99.1 2 exhibit991.htm EX-99.1 Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND INITIATES 2021 FINANCIAL GUIDANCE SAN DIEGO—Maravai LifeSciences Holdings, Inc. (Maravai)(NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and the full

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39725 (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 56600D107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate b

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Tit

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D 107 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the approp

AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G

EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Class A common stock of Maravai LifeSciences Holding Corp. may be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. Date: February 11, 2021 MARAVAI LIFE SCIENCES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Maravai LifeSciences Holdings Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 56600D107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed

Registration Rights Agreement, dated November 24, 2020, by and among Maravai LifeSciences Holdings, Inc. and the other signatories party thereto (incorporated by reference to Exhibit 4.1 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020).

EX-4.1 Exhibit 4.1 MARAVAI LIFESCIENCES HOLDINGS, INC. REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of November 24, 2020 among Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), each of the investors listed on the signature pages hereto under the caption “Sponsor Investors” (collectively, the “Sponsor Investors”), and each

Amended and Restated Certificate of Incorporation of Maravai LifeSciences Holdings, Inc. dated November 19, 2020 (incorporated by reference to Exhibit 3.1 to Maravai Life Sciences Holdings, Inc.’s Form 8-K filed on November 25, 2020)

EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MARAVAI LIFESCIENCES HOLDINGS, INC. * * * * * Carl Hull, being the Chief Executive Officer of Maravai LifeSciences Holdings, Inc., a corporation duly organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY as follows: FIRST: The present name of

Tax Receivable Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. and the other signatories party thereto (incorporated by reference to Exhibit 10.1 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020).

Exhibit 10.1 EXECUTION VERSION TAX RECEIVABLE AGREEMENT BY AND AMONG MARAVAI LIFESCIENCES HOLDINGS, INC., CERTAIN OTHER PERSONS NAMED HEREIN, AND THE AGENT DATED AS OF NOVEMBER 19, 2020 TABLE OF CONTENTS Page RECITALS 1 ARTICLE I DEFINITIONS 2 Section 1.1 Definitions 2 Section 1.2 Other Definitional and Interpretative Provisions 10 ARTICLE II DETERMINATION OF CERTAIN REALIZED TAX BENEFITS 10 Secti

Underwriting Agreement, dated as of November 19, 2020, among Maravai LifeSciences Holdings, Inc., Maravai Topco Holdings, LLC and Morgan Stanley & Co. LLC, Jefferies LLC and Goldman Sachs & Co. LLC, as representatives for the underwriters named therein.

EX-1.1 Exhibit 1.1 60,000,000 Shares MARAVAI LIFESCIENCES HOLDINGS, INC. CLASS A COMMON STOCK (PAR VALUE $0.01 PER SHARE) UNDERWRITING AGREEMENT November 19, 2020 1 November 19, 2020 Morgan Stanley & Co. LLC Jefferies LLC Goldman Sachs & Co. LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o Goldman Sachs & Co. LLC 20

Director Nomination Agreement, dated as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc. and the other signatories party thereto (incorporated by reference to Exhibit 10.5 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020).

EX-10.5 Exhibit 10.5 DIRECTOR NOMINATION AGREEMENT THIS DIRECTOR NOMINATION AGREEMENT (this “Agreement”) is made and entered into as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (“MLSH 1”), Maravai Life Sciences Holdings 2, LLC, a Delaware limited liability c

Employment Agreement of Carl W. Hull, dated November 24, 2020, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Carl W. Hull (incorporated by reference to Exhibit 10.8 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020).

EX-10.8 Exhibit 10.8 EXECUTION VERSION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Carl W. Hull (“Executive”). Capitalized terms used but not otherwise defined herein sh

Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

EX-99.1 Exhibit 99.1 Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares SAN DIEGO, Calif. - November 24, 2020 - Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of its initial public

Employment Agreement of Kevin Herde, dated November 24, 2020, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Kevin Herde (incorporated by reference to Exhibit 10.9 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020).

EX-10.9 11 d31788dex109.htm EX-10.9 Exhibit 10.9 EXECUTION VERSION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Kevin Herde (“Executive”). Capitalized terms used but not

Second Amended and Restated Limited Liability Agreement of Maravai Topco Holdings, LLC, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. and the other signatories party thereto (incorporated by reference to Exhibit 10.3 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020).

EX-10.3 Exhibit 10.3 EXECUTION VERSION MARAVAI TOPCO HOLDINGS, LLC SECOND AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of November 19, 2020 THE UNITS ISSUED PURSUANT TO THIS SECOND AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. SUCH UNITS MAY NOT BE S

Employment Agreement of Brian Neel, dated November 24, 2020, among Maravai LifeSciences Holdings, Inc., TriLink Biotechnologies, LLC and Brian Neel (incorporated by reference to Exhibit 10.10 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020).

EX-10.10 Exhibit 10.10 EXECUTION VERSION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), TriLink Biotechnologies, LLC, a Delaware limited liability company (“Employer”), and Brian Neel (“Executive”). Capitalized terms used but not otherwise defined herein shall ha

Exchange Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. and the other signatories party thereto (incorporated by reference to Exhibit 10.2 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020).

Exhibit 10.2 EXECUTION VERSION EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (as it may be amended from time to time in accordance with the terms hereof, this “Agreement”), dated as of November 19, 2020 and effective as of immediately prior to the consummation of the IPO (as defined below) (the “Effective Time”), is made by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “C

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2020 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorpor

Amended and Restated Bylaws of Maravai LifeSciences Holdings, Inc. dated November 19, 2020 (incorporated by reference to Exhibit 3.2 to Maravai Life Sciences Holdings, Inc.’s Form 8-K filed on November 25, 2020).

EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF MARAVAI LIFESCIENCES HOLDINGS, INC. A Delaware corporation (Adopted as of November 19, 2020) ARTICLE I OFFICES Section 1. Offices. Maravai LifeSciences Holdings, Inc. (the “Corporation”) may have an office or offices other than its registered office at such place or places, either within or outside the State of Delaware, as the Board of Directors o

Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.2 to Maravai LifeSciences Holdings, Inc.’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on November 23, 2020).

EX-10.2 Exhibit 10.2 Final Version MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I PURPOSE The Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the “Plan”) is intended to assist Eligible Employees of Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), and its Designate

Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to Maravai LifeSciences Holdings, Inc.’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on November 23, 2020).

EX-10.1 Exhibit 10.1 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN ARTICLE I PURPOSE The purpose of this Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan is to promote the success of the Company’s business for the benefit of its stockholders by enabling the Company to offer Eligible Individuals cash and stock-based incentives in order to attract, retain, and reward

60,000,000 Shares Class A Common Stock

424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-249733 60,000,000 Shares Class A Common Stock This is the initial public offering of shares of Class A common stock of Maravai LifeSciences Holdings, Inc., par value $0.01 per share. Maravai LifeSciences Holdings, Inc. is offering 60,000,000 shares of its Class A common stock to be sold in the offering. Prior to this off

- S-8

S-8 As filed with the Securities and Exchange Commission on November 23, 2020 Registration No.

Form 8-A

8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 85-2786970 (I.R.S. Employer Identification

- S-1MEF

S-1MEF As filed with the Securities and Exchange Commission on November 19, 2020 No.

-

CORRESP Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Jefferies LLC 520 Madison Avenue New York, New York 10022 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 November 16, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Christine Torney Lynn Dicker Laura Crotty Suzanne Ha

-

CORRESP MARAVAI LIFESCIENCES HOLDINGS, INC. November 16, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-1090 Attention: Christine Torney Lynn Dicker Laura Crotty Suzanne Hayes Re: Maravai LifeSciences Holdings, Inc. Registration Statement on Form S-1 Originally Filed October 29, 2020 File No. 333-249733 Ladi

Consent of Anat Ashkenazi

EX-99.10 Exhibit 99.10 The undersigned hereby consents to being named in the registration statement on Form S-1 and in all subsequent amendments and post-effective amendments or supplements thereto and in any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Registration Statement”) of Maravai

Form of Stock Option Grant Notice and Stock Option Agreement (incorporated by reference to Exhibit 10.7 to Amendment No. 2 to Maravai LifeSciences Holdings, Inc.’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on November 13, 2020).

EX-10.7 Exhibit 10.7 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN STOCK OPTION GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”)

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.27 to Amendment No. 2 to Maravai LifeSciences Holdings, Inc.’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on November 13, 2020).

EX-10.27 Exhibit 10.27 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Pa

- S-1/A

S-1/A Table of Contents As filed with the Securities and Exchange Commission on November 13, 2020 No.

Form of Amended and Restated Bylaws of Maravai LifeSciences Holdings, Inc. (incorporated by reference to Exhibit 3.2 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (No. 333-249733), filed with the Commission on November 9, 2020)

EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF MARAVAI LIFESCIENCES HOLDINGS, INC. A Delaware corporation (Adopted as of [•], 20[•]) ARTICLE I OFFICES Section 1. Offices. Maravai LifeSciences Holdings, Inc. (the “Corporation”) may have an office or offices other than its registered office at such place or places, either within or outside the State of Delaware, as the Board of Directors of the C

- S-1/A

S-1/A As filed with the Securities and Exchange Commission on November 9, 2020 No.

Form of Second Amended and Restated Limited Liability Agreement of Maravai Topco Holdings, LLC

EX-10.10 Exhibit 10.10 MARAVAI TOPCO HOLDINGS, LLC SECOND AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of [•], 2020 THE UNITS ISSUED PURSUANT TO THIS SECOND AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. SUCH UNITS MAY NOT BE SOLD, TRANSFERRED, ASSIGN